Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States

INTRODUCTION: The Food and Drug Administration (FDA) approved certolizumab-pegol, the first biologic for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), for use in the United States (US) in March of 2019. The objective of this study was to investigate biologic use and reasons f...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Sandoval, David, Holdsworth, Elizabeth, Booth, Nicola, Hunter, Theresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211225/
https://www.ncbi.nlm.nih.gov/pubmed/32328928
http://dx.doi.org/10.1007/s40744-020-00208-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211225/
https://www.ncbi.nlm.nih.gov/pubmed/32328928
http://dx.doi.org/10.1007/s40744-020-00208-5

Ejemplares similares